Close Menu

Breaking News

The new company will use Seer's Proteograph proteomic platform along with other omics data to develop and commercialize tests for cancer and other diseases.

The test can be used directly on any open instrument, including portable systems, and it allows for detection of pathogens in about 75 minutes.

The firm's RT-PCR-based COVID-19 tests will be administered at fixed sites and by mobile units across the state.

IncellDx has been developing a test for cytokine storm-related cytokines, which it said are elevated in COVID-19 patients who experience long-term symptoms.

The collaboration seeks to standardize SARS-CoV-2 assays by defining concentrations of antibodies to specific viral proteins to confer neutralization.

The company and its collaborators previously published a study linking saliva concentrations of multiple microRNAs with concussion duration and symptoms in children.

The Belgian home testing company said it will use the money to initiate clinical development for a urine-based self-test for chlamydia and gonorrhea.

Hologic intends to use the proceeds of the offering and available cash to refinance its existing 4.375 percent senior unsecured notes due in 2025.

Overall, GenMark's ePlex Respiratory Pathogen Panel 2 provides results for more than 20 viruses and bacteria, including SARS-CoV-2, flu A and B, RSV, and rhinovirus.

The company said that dried blood-spot sampling improves access to HIV diagnostic testing and care, particularly among HIV-infected people living in remote areas.

The company's mobile app provides automated COVID-19 screening and directs potential patients to testing locations for confirmatory testing.

The increased forecast is the result of continuing COVID-19 testing volumes along with recovery in its breast and skeletal business, Hologic said.

The company received Emergency Use Authorization from the US Food and Drug Administration last month for a SARS-CoV-2 total antibody test.

The company is selling 4,166,666 shares of its common stock at a price of $60 per share in the offering, which is expected to close Sept. 15.

FIND has convened the Access to COVID-19 Tools Accelerator Diagnostic Pillar to supply 500 million tests to countries in the next year.

The Swiss firm will offer 17,647,059 of its ordinary shares at $4.25 per share. It previously said it would offer $60 million worth of its shares.

The guidelines caution that there are "significant limitations" in the interpretation of polygenic risk scores and they should not be used in patient management.

 

News items for the in vitro diagnostics industry for the week of Sept. 7, 2020.

The contractors will provide limited coverage for ctDNA tests if the patient has a personal history of stage II to stage III colorectal cancer.

A new study aims to compare the detection performance of Helio Health's circulating tumor DNA assay with that of other screening modalities.

The investment bank said that the company's noninvasive genomic test for melanoma detection could capture a large market currently served by invasive biopsies.

LabCorp also entered into a lab services relationship with the healthcare system, through which it will provide reference testing for all the system's facilities and clinics.

Albertsons said that the planned national rollout follows the rapid adoption of the test kit during a pilot launch in three market areas.

The company intends to use the proceeds of the offering primarily to fund the ongoing development and commercialization of its MosaiQ diagnostic platform.

The BioCheck chemiluminescence tests can process human serum samples in 30 minutes to detect IgG and IgM antibodies.

Pages